Day 2- Thursday, September 11th - EST (Eastern Time, UTC-05:00
The RNA Leaders ‘Women in RNA (WiRNA) Forum’ is a dedicated space to empower and connect women and allies who are shaping the future of RNA research and therapeutics.
A round table breakfast to hear and share about career, research journeys and RNA inspirations in the space.
- Jeremy Little - Director, Custom Oligonucleotides, Chemgenes
Discuss current regulatory hurdles and evolving guidelines impacting oligonucleotide drug development
Explore strategies for navigating regulatory pathways and fostering collaboration between industry, patient advocacy groups and regulatory agencies
Examine best practices for demonstrating safety, efficacy, and quality of oligonucleotide therapeutics throughout the development lifecycle
- Fred Fleitz - Group Vice President, CMC, Arrowhead Pharmaceuticals
- YanLing He, DMSci. PhD. - Executive Director, TM Profiling Head CVM, Novartis
- Bao Cai, PhD - Former Executive Director, Process Development, Sarepta Therapeutics
- Shiva Adhikari - Lead Senior Scientist, Process Development, Axolabs
- Bao Cai, PhD - Former Executive Director, Process Development, Sarepta Therapeutics
- Andrew Varley - Director, The University of British Columbia
Explore steps must the industry take to drive progress of personalised cancer mRNA vaccines and therapeutics?
Allogenic or autologous? Where is the industry placing its bets
Discuss to what extent delivery is hindering the progress of mRNA therapeutics and vaccines for cancer
Review the progress that has been made in mRNA-encoded immunotherapies
Insight into the future of mRNA therapeutics and vaccines for cancer patients, including 2026 milestones
- Thaminda Ramanayake - CBO, CureVac
- Daniel Getts - CEO, Myeloid Therapeutics
- Sally Werner - CEO, Cancer Support Community
- Shyam Kumar Gudey - Editor, Frontiers in Molecular Medicine (former Principle Scientist, Moderna), Moderna
- Anna-Rose Welch - Editorial and Community Director Advancing RNA, Life Science Connect
Overview of the Cancer Support Community Massachusetts
Insight into the patient advocacy process to support clinical trials for cancer therapeutics
- Sally Werner - CEO, Cancer Support Community
- Chris Gothard - Marketing Director, Sinopep-Allsino Biopharmaceutical Co., Ltd.
Designing del-brax, an antibody-oligonucleotide conjugate, to efficiently deliver siRNA to muscle and target DUX4, the root cause of FSHD.·
Clinical trial results demonstrating improved functional mobility and muscle strength in this rare, progressive neuromuscular disorder.
Evaluating the potential of Avidity’s platform for other genetic disorders and its potential to reshape RNA delivery.
- Rocio Martin - Senior Vice President, Global Program Head - FSHD, Avidity Biosciences
- Discuss siRNA synthesis by assembly of multiple short, single-stranded RNA fragments into the desired double-stranded RNA duplex using ligation
Compare various ligation approaches with a particular focus on substrate design. In combination with double-stranded RNA ligase engineering and protocol optimization, such integrated process development can increase target drug substance yield and reduce manufacturing costs
Process performance will be demonstrated on the synthesis of a commercially approved siRNA asset
- Stefan Lutz, Ph.D. - Senior Vice President, Research, Codexis
- Explore innovative RNAi-lipid conjugates targeting immune cell PD-L1 for refractory cancer treatment, focusing on pre-clinical discovery and efficacy of a novel RNAi compound.
- Delve into the compound's mechanism of action and its potential to overcome immunotherapy resistance, highlighting promising pre-clinical results.
- Unveil the strategic clinical trial design, outlining the approach for translating this cutting-edge therapy from laboratory to patient care in challenging cancer cases.
- Shanthi Ganesh - Director, Novo Nordisk
- Edo Kon - Director of Business Development, RiboX Therapeutics
Exploring the first-ever clinical stage circRNA therapeutic, RXRG001, for the treatment of HNC patients with radiation-induced xerostomia and hyposalivation.
- Weiyi Zhang - CEO & CSO, RiboX Therapeutics
- Randall Hyer - Chief Executive Officer, Merlin Biotech
Exploring a cutting-edge RNA design platform, which enables the creation of optimized RNA sequences for immunomodulation, enhancing the efficacy of next-generation mRNA vaccines and RNA-based protein therapeutics
- Gilles Besin, Ph.D. - Chief Scientific Officer, Orbital Therapeutics
- Anat Biran - Associate Director of Process and Analytical Development, Intellia Therapeutics
- GenAI-based gRNA design drives exquisite target editing and specificity to enable therapeutic application for mutation correction or disruption of pathogenic proteins
- Systemic administration of RNAfix with a novel AAV5-based capsid crosses the blood-brain-barrier and demonstrates broad RNA editing in neurons across the CNS, reaching 90% in deep brain regions
- Taken together, the RNAfix platform unlocks potential treatments for rare and common CNS diseases
- Brian Booth - Associate Director, Shape Therapeutics
- Korro Bio is a biopharmaceutical company focused on developing a new class of genetic medicines that utilize RNA editing to treat diseases of the liver, CNS, and beyond
- Korro’s OPERA (Oligonucleotide Promoted Editing of RNA) platform is a differentiated approach to identifying highly potent RNA editing oligonucleotides called CHORDs
- KRRO-110, the company’s first clinical candidate, is potentially a best-in-class therapeutic for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder affecting the lungs and the liver
- Todd Chappell - COO, Korro Bio
- The FORCETM platform enables TfR1-mediated delivery of oligonucleotides and other payloads to muscle and CNS.
- We leveraged the FORCE platform to develop DYNE-101 and DYNE-251 as potential treatments for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively.
- Clinical data in both programs support the potential of the FORCE platform to deliver functional improvement in serious neuromuscular disorders.
- Oxana Beskrovnaya, Ph.D. - Chief Innovation Officer, Dyne Therapeutics
- Vutrisiran, a subcutaneously administered RNA interference therapeutic agent that inhibits the production of hepatic transthyretin, is in development for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a progressive, fatal disease. HELIOS-B, the Phase 3 trial of vutrisiran in ATTR-CM, randomized 655 patients 1:1 to vutrisiran (25 mg) or placebo every 12 weeks for up to 36 months. The primary endpoint was a composite of all-cause mortality (ACM) and recurrent cardiovascular events; secondary endpoints included ACM and the change from baseline to month 30 in the distance walked in 6 minutes (6MWD, a measure of exercise capacity) and in the score on the Kansas City Cardiomyopathy Questionnaire (KCCQ-OS, a heart failure-specific patient-reported outcome). These endpoints were assessed in both the overall population and the monotherapy population (the patients who at study baseline were not receiving the TTR stabilizer, tafamidis, at the time the only approved treatment for ATTR-CM). As announced in June 2024, HELIOS-B met all primary and secondary endpoints: vutrisiran reduced the risk of the composite primary endpoint in the overall and monotherapy populations by 28% (p=0.012)and 33% (p=0.016), respectively; reduced the risk of ACM by 35% (p=0.010) and 36% (p=0.045); improved the 6MWD relative to placebo by 26 m (p<0.001)and 32 m (p<0.001); and improved KCCQ-OS relative to placebo by 5.8 points (p<0.001) and 8.7 points (p<0.001). The overall incidence of AEs was similar in vutrisiran- and placebo-treated patients, while the incidence of SAEs was lower in vutrisiran-treated patients. Collectively, these results indicate the safety and efficacy of vutrisiran in the treatment of ATTR-CM, and formed the basis for the global approval of vutrisiran in this indication, including, to date, in the US, EU, UK, Japan, and Brazil.
- John Vest - SVP, Alnylam Pharmaceuticals
- Argonaute RNA's revolutionary bispecific technology simultaneously silences two target genes with a single therapeutic, achieving >90% mRNA knockdown of both targets and addressing the critical limitation of conventional therapies that improve either steatosis or dyslipidemia at the expense of the other
- The company's proprietary linker technology demonstrates exceptional safety profile with no inflammatory markers while delivering dramatic LDL-C reduction that predicts >50% decrease in major adverse cardiovascular events, positioning this therapeutic as a breakthrough solution for ASCVD and MASH/MASLD patients
• Optimizing self-replicating RNA and manufacturing drive and increase in immunogenicity and safety for a best-in-class therapeutic index
• Achieving an improved therapeutic index drives advantages in vaccines targeting multiple antigens in complex pathogens or combination vaccines
• Unlocking optimized self-replicating RNA have durability that shows potential to exceed conventional vaccine technology
- Nathaniel Wang - CEO, Replicate Bioscience
- STX-001 (intratumoral LNP repRNA IL-12 delivery) clinical data
- STX-003 (intravenous LNP repRNA IL-12 delivery) preclinical data
- Tasuku Kitada - President and Head of R&D, Strand Therapeutics
- Daniel Getts - CEO, Myeloid Therapeutics
The Investor Perspective
Securing capital is difficult, especially in an economically challenging environment, so it is important to understand how investment decisions are made.
In this workshop, we will walk through how to build a great investor deck and leverage those components as a backdrop to discuss how investors evaluate biotechs for potential investment. We will also highlight current trends in investment
When you complete this workshop you should have an understanding of the following:
-How investors evaluate opportunities
-Questions to ask when seeking investment
-Investment trends
- Renee Williams - Managing Partner, Williams Biotech Consulting, LLC
- James Carroll - Managing Director - Life Science Investments, Wharton Alumni Angels
- Colin Freund - Partner, Delin Ventures
- Prateek Katti - Investor, Newpath Partners
- Brendan Kelly - Principal, Lightstone Ventures
Uncover innovative partnership paradigms and strategic approaches that catalyze breakthroughs and expedite the evolution of RNA-based therapeutics, with a spotlight on emerging opportunities in the Asia-Pacific and European regions and established collaborations in North America.
Dissect the critical components of high-impact collaborations among biotech firms, pharmaceutical giants, and key industry players within the global RNA ecosystem.
Pinpoint promising avenues and navigate potential hurdles in forging transcontinental strategic alliances, particularly between North American companies to propel RNA research, optimize manufacturing processes, and enhance clinical translation efforts.
Examine case studies of successful local and international partnerships that have leveraged diverse expertise, to accelerate RNA therapeutic development and market access. Highlight strategies for fostering robust, long-term collaborations in the RNA pharma landscape.
- Jay Stella - Chief Business Officer and acting Chief Financial Offer, Strand Therapeutics Inc
- Karina Thorn - Corporate Vice President, Head of Research, Global Nucleic Acid Therapies Research, Novo Nordisk
- Michelle Hall - Associate VP - Genetic Medicine Research, Eli Lilly & Company
- Malgorzata Gonciarz - Global Head xRNA Therapeutics, Novartis
- Daniel Abernathy - Director, McQuade Center for Strategic Research & Development, Otsuka
- Exploring the state of mRNA innovation: Discuss advancements in therapeutics, vaccines, and editing technologies, while addressing the impact of geopolitical factors, market trends, and emerging opportunities in the US.
- Strategies to overcome challenges: Gain insights into navigating regulatory hurdles, mitigating supply chain disruptions, and securing funding to drive successful mRNA product development.
- Case studies in mRNA technologies: Reflect on successful applications, such as personalized cancer vaccines and RNA editing, to understand their impact and potential for future innovation.
- Clay Alspach - Executive Director, Alliance for mRNA Medicines
- Roberta Duncan - Chief Strategy Officer, Arcturus Therapeutics
- Michelle Hall - Associate VP - Genetic Medicine Research, Eli Lilly & Company
- Sadik Kassim - Chief Technology Officer, Danaher Genomic Medicines
- Sudhir Agrawal - President and Founder, Arnay Sciences